 |
| Weekly News | More » |
 |
Sorafenib Active in Advanced Breast Cancer
Elsevier Global Medical News, 2009 Oct 1, P Wendling
Sorafenib, an oral agent that targets multiple tyrosine protein kinases, has demonstrated activity in breast cancer for the first time.
|
Targeted Therapy PLX4032 Takes Center Stage in Metastatic Melanoma
Elsevier Global Medical News, 2009 Oct 1, P Wendling
EXPERT COMMENTARY
An investigational agent that targets the BRAF mutation has shown impressive results in a second phase I melanoma trial.
|
Metformin Being Investigated as Possible Anticancer Treatment
Elsevier Global Medical News, 2009 Oct 1, M Tucker
The glucose-lowering drug metformin is increasingly showing an anticancer effect.
|
Senate Finance Committee Rejects Public Plan Option
Elsevier Global Medical News, 2009 Sept 30, A Ault
Supporters believe a public plan option will resurface and be included when the health care reform bill is brought to the full Senate for a vote.
|
Groups Back CMS Proposal to Ease Restrictions on PET for Cervical Cancer
The Gray Sheet, 2009 Sept 28, M Hogan
Oncologists, imaging groups, and private payers strongly support the CMS proposal to lift coverage-with-evidence-development requirements.
|
Statistical Model Helps Men Weigh Pros, Cons of PSA Testing
Elsevier Global Medical News, 2009 Sept 28, MA Moon
A statistical model may help men and their physicians decide whether the benefits of annual prostate-specific antigen testing outweigh the negatives.
|
Study: Physicians Don't Detail PSA Screening For Patients
Elsevier Global Medical News, 2009 Sept 28, MA Moon
Men who have undergone or declined prostate-specific antigen screening say they often received only limited information about the test from their physicians.
|
Pralatrexate Is Approved for Peripheral T-Cell Lymphoma
Elsevier Global Medical News, 2009 Sept 25, E Mechcatie
Pralatrexate has been approved for use as a single agent for treating patients with refractory or relapsed peripheral T-cell lymphoma.
|
Panel Seeks Clarity Regarding Ductal Carcinoma in Situ
Elsevier Global Medical News, 2009 Sept 24, K Wachter
The most urgent research need is identification of patient subsets that may require less therapeutic intervention without sacrificing outcomes.
|
|
| | |
| NEW CME
Earn valuable credits by participating in these case-based online programs in renal cell carcinoma and leukemia.
VISIT SITE
| |
|
|
| | |
| ECCO/ESMO 2009
Conference news plus interviews with ECCO/ESMO officers.
| |
|
|
|
Week in Review
